Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 9/20 | 0.37 |
| ▸ | MEN1 | O00255 | 4/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL360213 | 0.99 | KMT2A (0.39) | KMT2AMEN1POLBEPHX2CYP2D6 | |
| SCHEMBL361567 | 0.97 | POLB (0.35) | KMT2AMEN1POLBEPHX2CYP2D6 | |
| SCHEMBL360069 | 0.94 | MEN1 (0.32) | KMT2AMEN1POLB | |
| SCHEMBL360067 | 0.88 | RORC (0.36) | KMT2AMEN1POLBEPHX2CYP2D6 | |
| SCHEMBL14953072 | 0.86 | P2RX7 (0.32) | — | |
| SCHEMBL360190 | 0.83 | THRB (0.33) | KMT2APOLBALDH1A1 | |
| SCHEMBL14953141 | 0.79 | OPRM1 (0.34) | KMT2AMEN1POLBEPHX2LMNA | |
| SCHEMBL360171 | 0.77 | EPHX2 (0.35) | KMT2AMEN1POLBEPHX2ALDH1A1 | |
| SCHEMBL360133 | 0.77 | THRB (0.32) | POLBALDH1A1 | |
| SCHEMBL27907493 | 0.76 | PDE4B (0.34) | LMNATRPA1PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11312688-B2 | Pyrazole compound | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-04-26 | — | — | US | disclosed |
| US-20200308119-A1 | PYRAZOLE COMPOUND | NEUROINNOVATECH APS (DK) | 2020-10-01 | — | — | US | disclosed |
| US-10723703-B2 | Pyrazole compound | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-07-28 | — | — | US | disclosed |
| US-20190084938-A1 | PYRAZOLE COMPOUND | NEUROINNOVATECH APS (DK) | 2019-03-21 | — | — | US | disclosed |
| US-10183913-B2 | Pyrazole compound | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-01-22 | — | — | US | disclosed |
| US-10087146-B2 | Pyrazole compound | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-10-02 | — | — | US | disclosed |
| US-20180273489-A1 | PYRAZOLE COMPOUND | NEUROINNOVATECH APS (DK) | 2018-09-27 | — | — | US | disclosed |
| US-20170217902-A1 | PYRAZOLE COMPOUND | NEUROINNOVATECH APS (DK) | 2017-08-03 | — | — | US | disclosed |
| US-9663472-B2 | Pyrazole compound | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-05-30 | — | — | US | disclosed |
| EP-2594559-B1 | PYRAZOLE COMPOUND | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2016-02-24 | — | — | EP | disclosed |
| US-20140315971-A1 | PYRAZOLE COMPOUND | NEUROINNOVATECH APS (DK) | 2014-10-23 | — | — | US | disclosed |
| US-8809383-B2 | Pyrazole compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2014-08-19 | — | — | US | disclosed |
| US-20140031406-A1 | PYRAZOLE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2014-01-30 | — | — | US | disclosed |
| EP-2594559-A1 | PYRAZOLE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012008528-A1 | PYRAZOLE COMPOUND | 大日本住友製薬株式会社 (JP) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315971-A1 | PYRAZOLE COMPOUND | HTR2C, HTR3B, HTR3A | KMT2A 2238/4885MEN1 3975/4885POLB 4307/4885 |
| US-10183913-B2 | Pyrazole compound | HTR2C, HTR3B, HTR3A | KMT2A 2238/4885MEN1 3975/4885POLB 4307/4885 |
| US-20170217902-A1 | PYRAZOLE COMPOUND | HTR2C, HTR3B, HTR3A | KMT2A 2238/4885MEN1 3975/4885POLB 4307/4885 |
| US-11312688-B2 | Pyrazole compound | HTR2C, HTR3B, HTR3A | KMT2A 2238/4885MEN1 3975/4885POLB 4307/4885 |
| US-20200308119-A1 | PYRAZOLE COMPOUND | HTR2C, HTR3B, HTR3A | KMT2A 2238/4885MEN1 3975/4885POLB 4307/4885 |
| US-10723703-B2 | Pyrazole compound | HTR2C, HTR3B, HTR3A | KMT2A 2238/4885MEN1 3975/4885POLB 4307/4885 |
| US-20180273489-A1 | PYRAZOLE COMPOUND | HTR2C, HTR3B, HTR3A | KMT2A 2238/4885MEN1 3975/4885POLB 4307/4885 |
| US-20190084938-A1 | PYRAZOLE COMPOUND | HTR2C, HTR3B, HTR3A | KMT2A 2238/4885MEN1 3975/4885POLB 4307/4885 |
| US-10087146-B2 | Pyrazole compound | HTR2C, HTR3B, HTR3A | KMT2A 2238/4885MEN1 3975/4885POLB 4307/4885 |
| US-20140031406-A1 | PYRAZOLE COMPOUND | HTR2C, HTR3B, HTR3A | KMT2A 2238/4885MEN1 3975/4885POLB 4307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.